Developer docs
API playgroundTry for free, no card

Search company profiles

Arctic Therapeutics

Full company profile

uuid0000msw

Namestring
Arctic Therapeutics
Legal namestring
Arctic Therapeutics
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Arctic Therapeutics (ATx) is a privately held, clinical-stage biopharmaceutical company founded in 2015 by Dr. Hakon Hakonarson as a spin-off from the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia. Headquartered in Reykjavík, Iceland, with clinical operations in Akureyri and a commercial presence in Philadelphia, the company applies genomics to discover and develop small-molecule and peptide therapies for rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma. Its discovery engine combines Iceland's nationwide genealogy database, a government-licensed biobank, national hospital Electronic Health Records, and in-house genotyping/sequencing operations, layered onto the founder-built pediatric genomic biobank at CAG/CHOP.

The company has five mechanistically distinct pipeline programs. The lead asset AT-001 is an oral small-molecule designed to prevent and dissolve amyloid plaques and tau tangles, in development for hereditary cystatin C amyloid angiopathy (HCCAA) and Alzheimer's disease; an enhanced derivative NACA (NAC-amide) shows >10-fold higher potency than parent NAC in vitro. AT-004 is a topical acetylcholinesterase inhibitor targeting the non-neuronal cholinergic anti-inflammatory pathway in skin, with acne vulgaris as the lead indication and planned expansion to atopic dermatitis, psoriasis, and rosacea. Three earlier-stage programs round out the pipeline: AT-002 (SOCS1 KIR-domain peptide mimetic / JAK-STAT inhibitor for autoimmune disease), AT-003 (CLEC16A-targeted autophagy/mitophagy modulator), and AT-005 (RV-C / CDHR3 antagonist for severe asthma). AT-001 holds EMA Orphan Drug Designation in HCCAA and has EMA approval for Phase IIb/III (HCCAA) and Phase IIa (Alzheimer's); AT-004 is in a Phase IIa trial in Denmark with first patients enrolled in February 2026.

Arctic Therapeutics is pre-revenue and does not sell products commercially. Its operating model is funded by venture capital (€26.5M oversubscribed Series A closed January 2025, plus prior EIC Accelerator blended finance of approximately $13.3M in 2022/2023) and non-dilutive EIC grants. Clinical execution is outsourced to specialist CROs — Blueskin (a Sanos Group entity) for dermatology and NeuroScios (also Sanos Group) for CNS — with the Sanos CEO joining ATx's board. The planned revenue model is out-licensing and co-development of lead assets to large pharma partners, supported by an in-house business development function led by CBO/General Counsel Lisa DeMarco (ex-GSK). Geographic reach spans Iceland, Denmark, the broader EU clinical/regulatory ecosystem, and the United States.

Short descriptiontext

Arctic Therapeutics is an Icelandic clinical-stage biopharmaceutical company that applies genomics — leveraging Iceland's nationwide genealogy database and a licensed biobank — to discover and develop small-molecule and peptide therapies for dementia (AT-001), inflammatory skin diseases (AT-004), and autoimmune and respiratory conditions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersReykjavík, Iceland
HQ citystring
Reykjavík
HQ countrystring
Iceland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery development, genomic drug discovery, clinical stage biopharmaceuticals, small molecule therapeutics, inflammatory disease treatments
Industry2 codes
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Drug Discovery & Development
Social media profiles1 record
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Venture equity financing (Series A and earlier)
TypeLicensing Royalties
Description

Pre-revenue clinical-stage biopharma funded by venture capital. Closed a €26.5M oversubscribed Series A in January 2025 from EIC Fund, Kaldbakur, Sanos Group, Cerebrum DAO, The Lurie Family Foundation, Kerecis consortium and Chemometec. Prior EIC Accelerator blended finance included grant and equity (2022, $13.3M).

arctictherapeutics.com
2Non-dilutive grant funding
TypeProfessional Services
Description

European Innovation Council (EIC) Accelerator grant for clinical development of AT-001; multi-million euro value. Used to support Phase II development of dementia/Alzheimer's candidate.

arctictoday.com
3Future drug commercialization (planned)
TypeLicensing Royalties
Description

Planned revenue from out-licensing and co-development of lead assets AT-001 and AT-004. CBO/GC Lisa DeMarco is responsible for IP strategy, commercial, out-licensing and co-development efforts. No product sales yet.

arctictherapeutics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arctic Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule and peptide drug candidates for rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma, built on an applied genomics platform that leverages Iceland's nationwide genealogy database and a government-licensed biobank. Its two lead programs are AT-001, an oral amyloid-aggregation disruptor in Phase II trials for hereditary cystatin C amyloid angiopathy (HCCAA) and Alzheimer's disease, and AT-004, a topical acetylcholinesterase inhibitor in Phase IIa for acne vulgaris. Revenue is expected to come from out-licensing and co-development of these assets with large pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Closed €26.5M oversubscribed Series A financing from international investor syndicate (Jan 2025)
+4 more records
Product overview1 text field

Arctic Therapeutics is a clinical-stage biopharmaceutical company with a diversified pipeline of five investigational therapeutic programs (AT-001, AT-002, AT-003, AT-004, and AT-005) targeting rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma. AT-001 (oral small-molecule therapy for dementia) and AT-004 (topical therapy for inflammatory skin diseases) are the two lead clinical-stage programs currently in Phase II trials, while AT-002 (autoimmune/inflammatory diseases), AT-003 (CLEC16A-linked diseases), and AT-005 (severe asthma) are at earlier stages of development. The portfolio is built on applied genomics and was established as a spin-off from the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia, leveraging Iceland's nationwide genealogy database and biobank.

Product and service5 records
1AT-001
CategoryLead pipeline product (oral small-molecule therapy)
Description

AT-001 is an oral small-molecule therapy designed to address rare and common forms of dementia by preventing and dissolving amyloid plaques and tau tangles through destabilization of the inter/intra-molecular interactions that form and maintain these aggregates. It is being evaluated in hereditary cystatin C amyloid angiopathy (HCCAA), Alzheimer's disease, and other protein aggregation disorders, with multi-analyte biomarker readouts (Simoa pTau217/total Tau, NfL, SOBA toxic oligomers, MRI, PET).

2AT-004
CategoryLead pipeline product (topical therapy)
Description

AT-004 is a topical acetylcholinesterase inhibitor engineered to treat inflammatory skin diseases, with lead indication acne vulgaris. It targets the non-neuronal cholinergic system to modulate the cholinergic anti-inflammatory pathway and regulate pro-inflammatory cytokines such as TNF-α, with planned expansion into atopic dermatitis, psoriasis, and rosacea.

3AT-002
CategoryPipeline product (peptide therapy)
Description

AT-002 is a peptide mimetic of the KIR domain of SOCS1 acting as a potent JAK-STAT pathway inhibitor. It is in development for autoimmune uveitis and other autoimmune/inflammatory diseases such as lupus, psoriasis, juvenile dermatomyositis, and cytokine storm syndromes arising from CAR-T immunotherapy or COVID infection.

4AT-003
CategoryPipeline product (small-molecule modulator)
Description

AT-003 is a small-molecule mitophagy and autophagy modulator designed to counteract aberrant CLEC16A activity, which has been linked to 16 autoimmune diseases including lupus, rheumatoid arthritis, multiple sclerosis, and type 1 diabetes, as well as Parkinson's disease.

5AT-005
CategoryPipeline product (antiviral therapeutic)
Description

AT-005 is a novel therapeutic approach to prevent severe asthma attacks by targeting the C strain of Rhinovirus (RV-C), the most common trigger of these exacerbations in allergic asthma, by blocking the interaction of RV-C with its entry receptor CDHR3.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Investcorp-backed multi-niche CRO with ~200 employees in dermatology, CNS (via NeuroScios), and osteoarthritis. CEO Jeppe Ragnar Andersen joined ATx's board of directors as part of the Series A. Sanos entity Blueskin is conducting the Phase IIa AT-004 trial in Denmark. NeuroScios (Sanos subsidiary) supports AT-001 Alzheimer's program.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Swiss-based DAO focused on translational neuroscience for dementia. Participated in the Series A. Dr. Maryna Polyakova (Translational Neuroscience Lead at Cerebrum DAO) serves as an advisor to ATx.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

ATx is a 2015 spin-off from CAG; maintains close research relationships with CHOP and licenses intellectual property from CHOP. CAG is the largest pediatric biobank and genomic database in the world, founded by ATx's founder in 2006. Dr. Elizabeth J.K. Bhoj (CHOP Division of Human Genetics) serves as an advisor.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

European CRO specializing in dermatology, part of Sanos Group. Conducting the Phase IIa trial of topical AT-004 in acne vulgaris across three clinical sites in Denmark (60 participants over 12 weeks).

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Hosted the open-label Phase 2a clinical trial of NAC in HCCAA carriers between March 2019 and December 2021; 17 L68Q-CST3 mutation carriers enrolled. Hospital also serves as a site for the AT-001 Phase IIa study in Alzheimer's.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Austrian CRO specializing in Alzheimer's and CNS diseases, founded by Dr. Manfred Windisch; NeuroScios is a Sanos Group portfolio company. Supports AT-001 Alzheimer's clinical development. Dr. Manfred Windisch (NeuroScios CEO) serves as advisor to ATx.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharma developing small molecules for Alzheimer's, Parkinson's, and rare neurological diseases including Rett syndrome. Comparable to Arctic Therapeutics' small-molecule, CNS-focused, clinical-stage asset profile targeting dementia and orphan neuro indications.

TypeBroad incumbent
Description

Established commercial rare-disease biopharma with multiple approved enzyme-replacement and gene therapies. Comparable to Arctic Therapeutics' orphan-drug strategy in HCCAA and its rare-disease regulatory pathway, though at a far larger scale and with commercial products.

TypeBroad incumbent
Description

Established commercial biopharma pioneering RNAi-based therapeutics, founded on genomics-driven target discovery. Comparable to Arctic Therapeutics on the genomics-first drug discovery paradigm and the early-stage-to-commercial trajectory via platform technology.

TypeBroad incumbent
Description

CNS-focused biopharma (acquired by Biogen in 2024) developing CNS therapeutics for depression and neurological disorders. Comparable to Arctic Therapeutics on CNS drug development, clinical execution via CRO partners, and small-molecule CNS drug discovery.

TypeDirect peer
Description

Clinical-stage Swiss biopharma developing first-in-class therapeutics for neurodegenerative diseases including Alzheimer's and rare dementia, with multiple programs targeting amyloid, tau, and neuroinflammation. Directly comparable to Arctic Therapeutics' AT-001 amyloid-disruption approach and dementia focus.

TypeDirect peer
Description

Clinical-stage biotech focused on neurodegeneration with genetically validated targets and BBB-penetrant small molecules. Comparable to Arctic Therapeutics on genomics-driven CNS drug discovery and the strategy of leveraging genetic insights for first-in-class neurodegenerative therapeutics.

TypeDirect peer
Description

Late-stage commercial dermatology biopharma with topical small-molecule treatments for inflammatory skin diseases including atopic dermatitis, seborrheic dermatitis, and psoriasis. Directly comparable to Arctic Therapeutics' AT-004 topical anti-inflammatory platform targeting acne vulgaris and adjacent dermatology indications.

TypeEmerging player
Description

Clinical-stage biotech developing pridopidine for Huntington's disease and ALS. Comparable to Arctic Therapeutics as a small, clinical-stage CNS biopharma with genetically validated neuro targets pursuing orphan or rare-disease CNS indications.

TypeDirect peer
Description

Clinical-stage biotech developing protein-misfolding and amyloid-targeted therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Directly comparable mechanism space to AT-001 (amyloid/tau disruption) and similar small-cap, clinical-stage biopharma profile.

10Cassava Sciences
TypeDirect peer
Description

Clinical-stage biopharma developing simufilam for Alzheimer's disease. Comparable clinical-stage, CNS-focused, small-molecule Alzheimer's drug developer with similar market capitalization profile and Phase II/III clinical execution model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arctic Therapeutics

Drug Discovery & Developmentarctictherapeutics.com

Arctic Therapeutics is an Icelandic clinical-stage biopharmaceutical company that applies genomics — leveraging Iceland's nationwide genealogy database and a licensed biobank — to discover and develop small-molecule and peptide therapies for dementia (AT-001), inflammatory skin diseases (AT-004), and autoimmune and respiratory conditions.

What Arctic Therapeutics does

Arctic Therapeutics (ATx) is a privately held, clinical-stage biopharmaceutical company founded in 2015 by Dr. Hakon Hakonarson as a spin-off from the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia. Headquartered in Reykjavík, Iceland, with clinical operations in Akureyri and a commercial presence in Philadelphia, the company applies genomics to discover and develop small-molecule and peptide therapies for rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma. Its discovery engine combines Iceland's nationwide genealogy database, a government-licensed biobank, national hospital Electronic Health Records, and in-house genotyping/sequencing operations, layered onto the founder-built pediatric genomic biobank at CAG/CHOP.

The company has five mechanistically distinct pipeline programs. The lead asset AT-001 is an oral small-molecule designed to prevent and dissolve amyloid plaques and tau tangles, in development for hereditary cystatin C amyloid angiopathy (HCCAA) and Alzheimer's disease; an enhanced derivative NACA (NAC-amide) shows >10-fold higher potency than parent NAC in vitro. AT-004 is a topical acetylcholinesterase inhibitor targeting the non-neuronal cholinergic anti-inflammatory pathway in skin, with acne vulgaris as the lead indication and planned expansion to atopic dermatitis, psoriasis, and rosacea. Three earlier-stage programs round out the pipeline: AT-002 (SOCS1 KIR-domain peptide mimetic / JAK-STAT inhibitor for autoimmune disease), AT-003 (CLEC16A-targeted autophagy/mitophagy modulator), and AT-005 (RV-C / CDHR3 antagonist for severe asthma). AT-001 holds EMA Orphan Drug Designation in HCCAA and has EMA approval for Phase IIb/III (HCCAA) and Phase IIa (Alzheimer's); AT-004 is in a Phase IIa trial in Denmark with first patients enrolled in February 2026.

Arctic Therapeutics is pre-revenue and does not sell products commercially. Its operating model is funded by venture capital (€26.5M oversubscribed Series A closed January 2025, plus prior EIC Accelerator blended finance of approximately $13.3M in 2022/2023) and non-dilutive EIC grants. Clinical execution is outsourced to specialist CROs — Blueskin (a Sanos Group entity) for dermatology and NeuroScios (also Sanos Group) for CNS — with the Sanos CEO joining ATx's board. The planned revenue model is out-licensing and co-development of lead assets to large pharma partners, supported by an in-house business development function led by CBO/General Counsel Lisa DeMarco (ex-GSK). Geographic reach spans Iceland, Denmark, the broader EU clinical/regulatory ecosystem, and the United States.

Arctic Therapeutics firmographics

Firmographics
Name
Arctic Therapeutics
Legal name
Arctic Therapeutics
Website
https://arctictherapeutics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Arctic Therapeutics is an Icelandic clinical-stage biopharmaceutical company that applies genomics — leveraging Iceland's nationwide genealogy database and a licensed biobank — to discover and develop small-molecule and peptide therapies for dementia (AT-001), inflammatory skin diseases (AT-004), and autoimmune and respiratory conditions.
Ownership category
akta.pro rank

Arctic Therapeutics industry classification

Industry
Product category
Drug Discovery & Development
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAJ
Rare Endocrine & Growth Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals

Keywords

  • Drug discovery development
  • Genomic drug discovery
  • Clinical stage biopharmaceuticals
  • Small molecule therapeutics
  • Inflammatory disease treatments

Where Arctic Therapeutics is headquartered

Location

Headquarters

HQ city
Reykjavík
HQ country
Iceland
HQ region
Europe

Offices3 records

Markets served

Arctic Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Venture equity financing (Series A and earlier): Pre-revenue clinical-stage biopharma funded by venture capital. Closed a €26.5M oversubscribed Series A in January 2025 from EIC Fund, Kaldbakur, Sanos Group, Cerebrum DAO, The Lurie Family Foundation, Kerecis consortium and Chemometec. Prior EIC Accelerator blended finance included grant and equity (2022, $13.3M).
  2. Non-dilutive grant funding: European Innovation Council (EIC) Accelerator grant for clinical development of AT-001; multi-million euro value. Used to support Phase II development of dementia/Alzheimer's candidate.
  3. Future drug commercialization (planned): Planned revenue from out-licensing and co-development of lead assets AT-001 and AT-004. CBO/GC Lisa DeMarco is responsible for IP strategy, commercial, out-licensing and co-development efforts. No product sales yet.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Arctic Therapeutics product offering

Product offering

Core offering

Arctic Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule and peptide drug candidates for rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma, built on an applied genomics platform that leverages Iceland's nationwide genealogy database and a government-licensed biobank. Its two lead programs are AT-001, an oral amyloid-aggregation disruptor in Phase II trials for hereditary cystatin C amyloid angiopathy (HCCAA) and Alzheimer's disease, and AT-004, a topical acetylcholinesterase inhibitor in Phase IIa for acne vulgaris. Revenue is expected to come from out-licensing and co-development of these assets with large pharmaceutical partners.

Product overview

Arctic Therapeutics is a clinical-stage biopharmaceutical company with a diversified pipeline of five investigational therapeutic programs (AT-001, AT-002, AT-003, AT-004, and AT-005) targeting rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma. AT-001 (oral small-molecule therapy for dementia) and AT-004 (topical therapy for inflammatory skin diseases) are the two lead clinical-stage programs currently in Phase II trials, while AT-002 (autoimmune/inflammatory diseases), AT-003 (CLEC16A-linked diseases), and AT-005 (severe asthma) are at earlier stages of development. The portfolio is built on applied genomics and was established as a spin-off from the Center for Applied Genomics (CAG) at the Children's Hospital of Philadelphia, leveraging Iceland's nationwide genealogy database and biobank.

Differentiator

Problem solved

Functional benefit

Products and services

  • AT-001 AT-001 is an oral small-molecule therapy designed to address rare and common forms of dementia by preventing and dissolving amyloid plaques and tau tangles through destabilization of the inter/intra-molecular interactions that form and maintain these aggregates. It is being evaluated in hereditary cystatin C amyloid angiopathy (HCCAA), Alzheimer's disease, and other protein aggregation disorders, with multi-analyte biomarker readouts (Simoa pTau217/total Tau, NfL, SOBA toxic oligomers, MRI, PET).
  • AT-004 AT-004 is a topical acetylcholinesterase inhibitor engineered to treat inflammatory skin diseases, with lead indication acne vulgaris. It targets the non-neuronal cholinergic system to modulate the cholinergic anti-inflammatory pathway and regulate pro-inflammatory cytokines such as TNF-α, with planned expansion into atopic dermatitis, psoriasis, and rosacea.
  • AT-002 AT-002 is a peptide mimetic of the KIR domain of SOCS1 acting as a potent JAK-STAT pathway inhibitor. It is in development for autoimmune uveitis and other autoimmune/inflammatory diseases such as lupus, psoriasis, juvenile dermatomyositis, and cytokine storm syndromes arising from CAR-T immunotherapy or COVID infection.
  • AT-003 AT-003 is a small-molecule mitophagy and autophagy modulator designed to counteract aberrant CLEC16A activity, which has been linked to 16 autoimmune diseases including lupus, rheumatoid arthritis, multiple sclerosis, and type 1 diabetes, as well as Parkinson's disease.
  • AT-005 AT-005 is a novel therapeutic approach to prevent severe asthma attacks by targeting the C strain of Rhinovirus (RV-C), the most common trigger of these exacerbations in allergic asthma, by blocking the interaction of RV-C with its entry receptor CDHR3.

Quantifiable outcome

  • Closed €26.5M oversubscribed Series A financing from international investor syndicate (Jan 2025)
  • +4 more outcomes

Companies that use Arctic Therapeutics

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Arctic Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature8 records

Arctic Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered flagship and core.

  • Sanos GroupflagshipStrategic or Co-development PartnerInvestcorp-backed multi-niche CRO with ~200 employees in dermatology, CNS (via NeuroScios), and osteoarthritis. CEO Jeppe Ragnar Andersen joined ATx's board of directors as part of the Series A. Sanos entity Blueskin is conducting the Phase IIa AT-004 trial in Denmark. NeuroScios (Sanos subsidiary) supports AT-001 Alzheimer's program.
  • Cerebrum DAOcoreStrategic or Co-development PartnerSwiss-based DAO focused on translational neuroscience for dementia. Participated in the Series A. Dr. Maryna Polyakova (Translational Neuroscience Lead at Cerebrum DAO) serves as an advisor to ATx.
  • Children's Hospital of Philadelphia / Center for Applied Genomics (CAG)flagshipStrategic or Co-development PartnerATx is a 2015 spin-off from CAG; maintains close research relationships with CHOP and licenses intellectual property from CHOP. CAG is the largest pediatric biobank and genomic database in the world, founded by ATx's founder in 2006. Dr. Elizabeth J.K. Bhoj (CHOP Division of Human Genetics) serves as an advisor.
  • Blueskin (Sanos Group)coreImplementation/ SI/ Consulting PartnerEuropean CRO specializing in dermatology, part of Sanos Group. Conducting the Phase IIa trial of topical AT-004 in acne vulgaris across three clinical sites in Denmark (60 participants over 12 weeks).
  • Landspitali University Hospital (Iceland)coreImplementation/ SI/ Consulting PartnerHosted the open-label Phase 2a clinical trial of NAC in HCCAA carriers between March 2019 and December 2021; 17 L68Q-CST3 mutation carriers enrolled. Hospital also serves as a site for the AT-001 Phase IIa study in Alzheimer's.
  • NeuroScios (Sanos Group portfolio company)coreStrategic or Co-development PartnerAustrian CRO specializing in Alzheimer's and CNS diseases, founded by Dr. Manfred Windisch; NeuroScios is a Sanos Group portfolio company. Supports AT-001 Alzheimer's clinical development. Dr. Manfred Windisch (NeuroScios CEO) serves as advisor to ATx.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Arctic Therapeutics competitors and assessment

Company assessment

Direct peers

  • Anavex Life Sciences: Clinical-stage biopharma developing small molecules for Alzheimer's, Parkinson's, and rare neurological diseases including Rett syndrome. Comparable to Arctic Therapeutics' small-molecule, CNS-focused, clinical-stage asset profile targeting dementia and orphan neuro indications.
  • AC Immune: Clinical-stage Swiss biopharma developing first-in-class therapeutics for neurodegenerative diseases including Alzheimer's and rare dementia, with multiple programs targeting amyloid, tau, and neuroinflammation. Directly comparable to Arctic Therapeutics' AT-001 amyloid-disruption approach and dementia focus.
  • Denali Therapeutics: Clinical-stage biotech focused on neurodegeneration with genetically validated targets and BBB-penetrant small molecules. Comparable to Arctic Therapeutics on genomics-driven CNS drug discovery and the strategy of leveraging genetic insights for first-in-class neurodegenerative therapeutics.
  • Arcutis Biotherapeutics: Late-stage commercial dermatology biopharma with topical small-molecule treatments for inflammatory skin diseases including atopic dermatitis, seborrheic dermatitis, and psoriasis. Directly comparable to Arctic Therapeutics' AT-004 topical anti-inflammatory platform targeting acne vulgaris and adjacent dermatology indications.
  • Prothena Corporation: Clinical-stage biotech developing protein-misfolding and amyloid-targeted therapies for neurodegenerative diseases including Alzheimer's and Parkinson's. Directly comparable mechanism space to AT-001 (amyloid/tau disruption) and similar small-cap, clinical-stage biopharma profile.
  • Cassava Sciences: Clinical-stage biopharma developing simufilam for Alzheimer's disease. Comparable clinical-stage, CNS-focused, small-molecule Alzheimer's drug developer with similar market capitalization profile and Phase II/III clinical execution model.

Broad incumbents

  • BioMarin Pharmaceutical: Established commercial rare-disease biopharma with multiple approved enzyme-replacement and gene therapies. Comparable to Arctic Therapeutics' orphan-drug strategy in HCCAA and its rare-disease regulatory pathway, though at a far larger scale and with commercial products.
  • Alnylam Pharmaceuticals: Established commercial biopharma pioneering RNAi-based therapeutics, founded on genomics-driven target discovery. Comparable to Arctic Therapeutics on the genomics-first drug discovery paradigm and the early-stage-to-commercial trajectory via platform technology.
  • Sage Therapeutics: CNS-focused biopharma (acquired by Biogen in 2024) developing CNS therapeutics for depression and neurological disorders. Comparable to Arctic Therapeutics on CNS drug development, clinical execution via CRO partners, and small-molecule CNS drug discovery.

Emerging players

  • Prilenia Therapeutics: Clinical-stage biotech developing pridopidine for Huntington's disease and ALS. Comparable to Arctic Therapeutics as a small, clinical-stage CNS biopharma with genetically validated neuro targets pursuing orphan or rare-disease CNS indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Arctic Therapeutics social profiles

Digital presence

Arctic Therapeutics compliance and trust

Trust signal

Compliance2 records

Arctic Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arctic Therapeutics leadership team

Management profile

Number of profiles

Profiles10 records

Arctic Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arctic Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arctic Therapeutics

What does Arctic Therapeutics do?

Arctic Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small-molecule and peptide drug candidates for rare and common forms of dementia, inflammatory skin diseases, autoimmune disorders, and severe asthma, built on an applied genomics platform that leverages Iceland's nationwide genealogy database and a government-licensed biobank. Its two lead programs are AT-001, an oral amyloid-aggregation disruptor in Phase II trials for hereditary cystatin C amyloid angiopathy (HCCAA) and Alzheimer's disease, and AT-004, a topical acetylcholinesterase inhibitor in Phase IIa for acne vulgaris. Revenue is expected to come from out-licensing and co-development of these assets with large pharmaceutical partners.

Is Arctic Therapeutics a public or private company?

Arctic Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Arctic Therapeutics founded?

Arctic Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Arctic Therapeutics based?

Arctic Therapeutics is headquartered in Reykjavík, Iceland, in the Europe region.

How does Arctic Therapeutics make money?

Three revenue lines are on record. Venture equity financing (Series A and earlier) is the primary driver. The others are non-dilutive grant funding and future drug commercialization (planned).

Who are Arctic Therapeutics's main competitors?

Direct peers on record are Anavex Life Sciences, AC Immune, Denali Therapeutics, Arcutis Biotherapeutics, Prothena Corporation and Cassava Sciences. Broad incumbents are BioMarin Pharmaceutical, Alnylam Pharmaceuticals and Sage Therapeutics. Prilenia Therapeutics is listed as an emerging player.

Does Arctic Therapeutics have an API?

No public API is recorded for Arctic Therapeutics.

What industry is Arctic Therapeutics in?

Arctic Therapeutics's product category is Drug Discovery & Development. Its primary akta.pro industry code is HLAIAIAJ, Rare Endocrine & Growth Disorder Therapies, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Arctic Therapeutics Raises $21.5 Million To Advance AT-002 And AT-003 Toward Clinical DevelopmentArctic Therapeutics raised an oversubscribed $21.5 million financing round led by Pekron, Sanos Group, Kaldbakur, and Landvættir. The funds will advance AT-002 and AT-003 toward clinical development, following a $31 million Series A. The company also continues partnering and out-licensing for its lead assets AT-001 and AT-004.Startup ResearcherArctic Therapeutics Closes Oversubscribed $21.5 Million Financing RoundArctic Therapeutics closed an oversubscribed $21.5 million financing round on October 21, 2026, led by Pekron, Sanos Group, Kaldbakur, and Landvættir. The capital will advance AT-002 and AT-003 toward clinical development, following a $31 million Series A. The company also acquired NB-001, now SYN-001, for its new Synaptiq Therapeutics.PRESSBEEArctic Therapeutics closes oversubscribed US$21.5 million financing ...Middle EastArctic Therapeutics closed an oversubscribed US$21.5 million financing round led by Pekron, Sanos Group, Kaldbakur, and Landvættir. The proceeds will be used for further development of its therapeutics, though specific details were not disclosed.BitlyArctic Therapeutics closes oversubscribed US$21.5 million financingArctic Therapeutics closed an oversubscribed US$21.5 million financing round led by Pekron, Sanos Group, Kaldbakur, and Landvættir. The proceeds will advance AT-002 and AT-003 toward clinical development, building on Phase II milestones for AT-001 and AT-004.PR NewswireArctic Therapeutics closes oversubscribed US$21.5 million financingArctic Therapeutics closed an oversubscribed US$21.5 million financing round led by Pekron, Sanos Group, Kaldbakur, and Landvættir. The proceeds will advance AT-002 and AT-003 toward clinical development, building on Phase II milestones for AT-001 and AT-004.PR NewswireArctic Therapeutics closes oversubscribed US$21.5 million financingArctic Therapeutics closed an oversubscribed US$21.5 million financing round led by Pekron, Sanos Group, Kaldbakur, and Landvættir. The proceeds will advance AT-002 and AT-003 toward clinical development, building on Phase II milestones for AT-001 and AT-004.news.cision.comArctic Therapeutics closes oversubscribed US$21.5 million financingArctic Therapeutics closed an oversubscribed US$21.5 million financing round led by Pekron, Sanos Group, Kaldbakur, and Landvættir. The proceeds will advance AT-002 and AT-003 toward clinical development, building on Phase II milestones for AT-001 and AT-004. The company also participated in the acquisition of Nobias Therapeutics' lead asset, now Synaptiq Therapeutics.Pulse 2.0Synaptiq Therapeutics Launches With Acquisition Of Clinical-Stage SYN-001 ProgramA consortium of European and US investors alongside Nobias Therapeutics announced the launch of Synaptiq Therapeutics, a privately held clinical-stage biotechnology company formed through the acquisition of Nobias' lead asset NB-001, now renamed SYN-001, for the treatment of neuropsychiatric symptoms associated with 22q11.2 Deletion Syndrome. The company, headquartered in Iceland and led by CEO Patrick Dougherty, will draw on Arctic Therapeutics' drug development platform and Sanos Group's clinical operations as it prepares to launch a Phase IIb trial across North America and Europe. SYN-001 demonstrated favorable safety and tolerability with statistically significant efficacy in certain patient subgroups in a prior Phase II trial, and received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA in 2024.news.cision.comSynaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 ProgramSynaptiq Therapeutics launched on July 23, 2026, after acquiring Nobias Therapeutics' lead asset SYN-001 for treating neuropsychiatric symptoms of 22q11.2 deletion syndrome. The company plans a Phase IIb trial and has not disclosed financial terms. SYN-001 received FDA orphan and rare pediatric disease designations in 2024.PR NewswireSynaptiq Therapeutics Launches with Acquisition of Clinical-Stage SYN-001 ProgramSynaptiq Therapeutics launched after acquiring Nobias Therapeutics' SYN-001 program for 22q11DS neuropsychiatric symptoms. The company plans a Phase IIb trial and has no disclosed financial terms. SYN-001 received FDA orphan and rare pediatric disease designations in 2024.